ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/302% above fair value
$11.17−0.08 (-0.71%)
Close on Nov 19, 2026Market cap $101.45MP/E 139.6Yield –
ImmuCell free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ImmuCell's free cash flow for the twelve months ending Jun 30, 2026 was $4.21M, up 138.9% year over year. For fiscal 2025 it was $1.22M. Over ten years it grew 21.1% a year on average. The highest annual figure on record is $1.22M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22M | – |
| FY2024 | Dec 31, 2024 | -$107.82K | – |
| FY2023 | Dec 31, 2023 | -$6.57M | – |
| FY2022 | Dec 31, 2022 | -$5.52M | – |
| FY2021 | Dec 31, 2021 | -$1.65M | – |
| FY2020 | Dec 31, 2020 | -$2.76M | – |
| FY2019 | Dec 31, 2019 | -$1.16M | – |
| FY2018 | Dec 31, 2018 | -$2.40M | – |
| FY2017 | Dec 31, 2017 | -$16.58M | – |
| FY2016 | Dec 31, 2016 | -$3.81M | -2203.7% |
| FY2015 | Dec 31, 2015 | $181.05K | – |
| FY2014 | Dec 31, 2014 | -$1.23M | -346.2% |
| FY2013 | Dec 31, 2013 | $500.96K | +626.1% |
| FY2012 | Dec 31, 2012 | $69.00K | – |
| FY2011 | Dec 31, 2011 | -$281.05K | – |
| FY2010 | Dec 31, 2010 | -$925.16K | – |
| FY2009 | Dec 31, 2009 | -$569.21K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.29M | +58.0% |
| Q1 FY2026 | Mar 31, 2026 | $3.40M | +172.8% |
| Q4 FY2025 | Dec 31, 2025 | $310.24K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.78M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.45M | +207.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.24M | +257.5% |
| Q4 FY2024 | Dec 31, 2024 | -$199.27K | – |
| Q3 FY2024 | Sep 30, 2024 | -$727.74K | – |
| Q2 FY2024 | Jun 30, 2024 | $471.04K | – |
| Q1 FY2024 | Mar 31, 2024 | $348.15K | – |
| Q4 FY2023 | Dec 31, 2023 | -$804.42K | – |
| Q3 FY2023 | Sep 30, 2023 | -$928.27K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$569.83K | – |
| Q1 FY2022 | Mar 31, 2022 | -$168.96K | – |
| Q4 FY2021 | Dec 31, 2021 | -$116.70K | – |
| Q3 FY2021 | Sep 30, 2021 | -$416.41K | – |
| Q2 FY2021 | Jun 30, 2021 | -$148.51K | – |
| Q1 FY2021 | Mar 31, 2021 | -$972.86K | – |
| Q4 FY2020 | Dec 31, 2020 | -$128.43K | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$93.39K | – |
| Q1 FY2020 | Mar 31, 2020 | -$394.69K | -181.8% |
| Q4 FY2019 | Dec 31, 2019 | -$738.05K | – |
| Q3 FY2019 | Sep 30, 2019 | -$466.29K | – |
| Q2 FY2019 | Jun 30, 2019 | -$436.39K | – |
| Q1 FY2019 | Mar 31, 2019 | $482.79K | – |
| Q4 FY2018 | Dec 31, 2018 | -$237.10K | – |
| Q3 FY2018 | Sep 30, 2018 | -$721.90K | – |
| Q2 FY2018 | Jun 30, 2018 | -$480.71K | – |
| Q1 FY2018 | Mar 31, 2018 | -$963.59K | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.72M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.84M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.68M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.16M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.12M | – |
See a number that looks wrong?